AZN - Astrazeneca/ Alexion deal earns mixed views on Wall Street

Alexion (ALXN) pops +31.2% in pre-market trading after AstraZeneca (AZN) announced over the weekend, it was acquiring the rare-disease specialist in a deal worth $39B.AstraZeneca’s US-listed shares have sunk -5.7% in pre-market, while in the U.K, the company’s London-listed stock trade -6.5% below in mid-day trading.Wall Street appears to have divided over the prospects of the deal where Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed on the Nasdaq, reflecting a premium of ~45% to Alexion’s closing share price on Friday.Upon completion, Alexion shareholders will own ~15% of the combined company, and according to the Financial Times, Alexion chief executive Ludwig Hantson is set to earn $56m from a golden parachute clause if he leaves following the deal’s completion.Many analysts believe, the deal, subject to shareholder approval, will not attract antitrust concerns given the lack of overlap between the portfolios of the two companies. Guggenheim says, “the proposed

For further details see:

Astrazeneca/ Alexion deal earns mixed views on Wall Street